AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine
In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to BRAF and/or MEK inhibition.
Check out our comprehensive panel of PDX models
4988_A tailored platform enables BRAF-targeted drug discovery and precision medicine_final - Copy
Related Content
Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored...
VIEW RESOURCEAntibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....
VIEW RESOURCE